EGFR and neoplasm: Molecular-targeted therapy with cetuximab, an anti-epidermal growth factor receptor-specific chimeric monoclonal antibody, has been also demonstrated to inhibit tumor growth, cancer cell invasion, angiogenesis, and metastasis, thereby improving overall survival in head and neck OSCC patients [36, 37].